In the absence of a submission from the holder of the marketing authorisation, elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (Genvoya®) cannot be endorsed for use within NHS Wales for the treatment of human immunodeficiency virus-1 (HIV-1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir, in children aged from 6 years to 12 years and with body weight at least 25 kg for whom alternative regimens are unsuitable due to resistance or toxicities.